Recipharm Annual report 2013
"Recipharm is well-placed, now that Big Pharma is focusing on its core businesses, outsourcing entire portfolios of established products, divesting the facilities where the products are manufactured.”
Recipharm is now in its 20th year of operations. The growth that our motivated and committed employees have achieved makes us well placed for further expansion. In what has been a fantastic period, we have seen a whole new industry emerge. Recipharm today is a customer-led CDMO with stable finances. This means that we can continue to grow, whilst providing reliable support to our customers, so that they can concentrate on their prioritised core business. Our objective is to continue to develop Recipharm into a world-leading CDMO, and we have a solid plan for reaching that goal. Strong, profitable growth.